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S U M M A R Y
Despite advances in medical care, mortality due to cerebral Nocardia abscesses remains unacceptably
high. The case of a typical immunocompromised patient, who deteriorated clinically despite optimal
antimicrobial treatment, is reported here. Adjuvant immunotherapy with interferon-gamma resulted in
partial restoration of the immune response and a corresponding clinical and radiographic recovery.
© 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Nocardiosis is a rare Gram-positive bacterial infection caused
by aerobic actinomycetes of the genus Nocardia. Nocardia species
can cause both localized and disseminated infection (Wilson,
2012). Mortality rates of up to 66% have been reported in patients
with multiple lesions (Lee et al., 2002). Because nocardiosis is
most commonly observed in individuals with immune defects
(Wilson, 2012), adjunctive immunotherapy is a potentially
attractive strategy to improve host defence and the outcome of
patients with disseminated nocardiosis. Interferon-gamma (IFN-
g), a well-known immunostimulatory cytokine (Leentjens et al.,
2013), has shown promising results in the adjunctive treatment of
other opportunistic infections (Delsing et al., 2014). Therefore,
IFN-g represents a promising candidate to improve the outcome of
invasive Nocardia infections. However, to date, no reports of
adjunctive treatment with IFN-g for patients with Nocardia
infections have been reported.
Case report
A 50-year-old male patient with multiple Nocardia cerebral
abscesses was referred to the university hospital because of clinical
deterioration despite adequate antimicrobial treatment. The
patient had been treated with high-dose corticosteroids over
the past 6 months for an unidentiﬁed interstitial pneumonitis. Two
months prior to admission to the university hospital, two cerebral
abscesses had been found on cerebral magnetic resonance imaging
(MRI). The largest lesion is depicted in Figure 1A. Stereotactic
cultures revealed Nocardia asteroides (conﬁrmed by 16S RNA
analysis: a 100% match with N. asteroides). Initial treatment
consisted of cefotaxime, ceftazidime, and metronidazole intrave-
nously, which was changed to high-dose trimethoprim–sulfa-
methoxazole (TMP–SMX, 1920 mg three times daily,
intravenously) as soon as culture results became available.
Additional susceptibility testing revealed the strain to be
susceptible to the prescribed antibiotics. In addition, meropenem
treatment was added at day 47 of admission after urine cultures
became positive for multi-resistant Escherichia coli. Despite this
treatment, the patient’s clinical condition deteriorated due to
exudation of the left abscess into the left ventricle. In addition,
after an initial decrease in size (Figure 1B), subsequent sequential
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MRI scans showed no further reduction in size of the lesions and
surrounding oedema (Figure 1C, D).
It was considered that the patient would beneﬁt from
adjunctive immunotherapy as ‘therapy of last resort’. Therefore,
IFN-g (Boehringer-Ingelheim, Arnhem, the Netherlands) treat-
ment was initiated on day 55 of admission (50 mg/m2 subcutane-
ously, three times weekly). Furthermore, 2 days after the initiation
of IFN-g therapy, ceftriaxone was started alongside TMP–SMX and
meropenem because of persistent fever. Four days later, merope-
nem was stopped, as no clear effects on the clinical course were
noted despite treatment for 14 days. Compared with the MRI
performed 1 week before the initiation of IFN-g treatment, the MRI
performed 14 days later showed a decrease in the right para-
ventricular lesion (Figure 1E). The fever disappeared 12 days after
the initiation of IFN-g treatment. However, despite combination
antimicrobial therapy (TMP–SMX and ceftriaxone), resolution of
the fever, and signs of improvement on radiography, the
cerebrospinal ﬂuid (CSF) remained purulent and hence intrathecal
amikacin was added. Within 2 weeks, the patient’s headache had
subsided and the CSF became normal; amikacin could be
discontinued. One week later, only trunk balance impairment
and vertigo with a tendency to fall remained. The patient’s
condition improved further, and 3.5 months after the initiation of
IFN-g treatment he was discharged. He was able to walk at this
time. MRI showed further improvement (Figure 1F). He was
discharged on TMP–SMX and IFN-g treatment, which were well
tolerated.
Unfortunately, 4 days after discharge the patient was read-
mitted because of free subdiaphragmatic air with pneumatosis
intestinalis, a rare complication of high-dose corticosteroid
administration. Abdominal surgery showed no additional cause
for the free air. He died 17 days later due to cardiovascular
problems that were not directly related to the Nocardia infection,
which was conﬁrmed on autopsy.
Immunological analysis
Although the patient had been treated with corticosteroids, his
personal and family histories were negative for immune
deﬁciencies. Additional testing revealed a CD4 lymphopenia
(140 cells/mm3) in the absence of HIV infection. This may have
been related to the steroid treatment, but a primary cause cannot
be excluded. Additional blood was collected to analyze immune
responses before and during IFN-g treatment (see Supplemen-
tary Material online for methods of blood sampling and cytokine
assays). Before IFN-g treatment, the capacity of peripheral blood
mononuclear cells (PBMCs) to produce cytokines upon ex vivo
stimulation with Candida albicans, lipopolysaccharide (LPS), and
phytohaemagglutinin (PHA) was severely blunted (Figure 2A–F).
IFN-g treatment was associated with an increased production of
Figure 1. Studies of the largest right paraventricular brain lesion by magnetic resonance imaging (MRI). (A) T1-weighted contrast-enhanced hyperintense MRI image of the
right brain lesion at admission on January 12, 2012 (size of lesion 25  22  20 mm, with extensive surrounding oedema). (B) Culture-guided initial treatment with
trimethoprim–sulfamethoxazole resulted in an initial decrease in size and reduction of the oedema (size of lesion 17  15 17 mm). However, subsequent imaging showed
little to no further reduction of the abscess: (C) size of lesion 15 13 19 mm, (D) size of lesion: 16  13 19 mm. Therefore, adjunctive immunotherapy with interferon-
gamma treatment was initiated on March 6. (E) MRI performed 12 days later showed a decrease in the right paraventricular lesion (size of lesion 12  13 17 mm). (F) Further
improvements were observed on MRI 3 weeks later (size of lesion 12  9  12 mm). All images are published with the permission of the patient’s legal representative.
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interleukin (IL)-1b, tumour necrosis factor alpha (TNF-a), IL-6, and
IL-10 by PBMCs stimulated with all three agents (Figure 2A–D). C.
albicans-induced ex vivo production of the T-helper 17 (Th17)
cytokines IL-17 and IL-22 was also increased, although to a lesser
extent (Figure 2E, F).
Discussion
This case report describes how adjunctive immunotherapy with
IFN-g resulted in augmentation of the innate immune response in
a patient with progressive Nocardia abscesses, which likely
contributed to his clinical recovery.
Patients with impaired cell-mediated immunity (including
hematopoietic stem cell transplant patients and patients
receiving long-term treatment with steroids) are at particularly
high risk of developing opportunistic infections, including
nocardiosis (Wilson, 2012). Immunotherapy to improve cell-
mediated immunity is therefore a promising therapy to improve
the outcomes of these patients. It has been demonstrated
previously that IFN-g has favourable effects on the outcomes
of sepsis patients who exhibit clear signs of suppression of
cellular immune responses, which renders them more vulnerable
to opportunistic infections (Leentjens et al., 2013). In addition,
IFN-g was found to restore the suppressed cytokine production in
vivo in humans in an experimental sepsis model (Leentjens et al.,
2013), and in patients with severe invasive fungal infections
(Delsing et al., 2014). In the present study, it was demonstrated
that IFN-g improved cellular immune responses in a patient with
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Figure 2. Cytokine production by peripheral blood mononuclear cells stimulated ex vivo with different agents before and during interferon-gamma treatment. IL,
interleukin; TNF, tumor necrosis factor; LPS, lipopolysaccharide; PHA, phytohaemagglutinin; IFN, interferon.
J. Leentjens et al. / International Journal of Infectious Diseases 59 (2017) 25–28 27
cerebral nocardiosis, and this correlated with an improvement in
the clinical outcome.
Taking into account all available human data, consisting of data
from retrospective studies and small case series, the most
appropriate therapeutic agent and treatment duration for Nocardia
infections remain to be established. In patients with central
nervous system (CNS) involvement, treatment options include
antimicrobial therapy alone, or antimicrobial therapy in combina-
tion with freehand or stereotactic aspiration, or craniotomy plus
enucleation.
With different Nocardia spp having different resistance proﬁles,
species identiﬁcation is crucial to determine the most suitable
antibiotic treatment (Brown-Elliott et al., 2006). In the case of CNS
involvement, therapy should obviously include drugs with
favourable penetration into the CNS (e.g., TMP–SMX and ceftriax-
one). In the patient presented here, meropenem instead of
ceftriaxone was started alongside TMP–SMX because of the
additional presence of multi-resistant E. coli in urine cultures.
Meropenem is also active against most Nocardia spp and can cross
the blood–brain barrier.
Despite appropriate combination therapy against Nocardia spp,
the patient’s condition deteriorated. The compromised status of the
immune response reﬂected by the impaired ex vivo cytokine
responses may, at least in part, explain his deterioration, and may
also be responsible for the high mortality among patients with
nocardiosis. Thus, the patient’s immunocompromised status may
have represented an important compromising factor, which was
improved by IFN-g treatment. However, in the current case, the
purulent ventricular involvement could also account for the lack of
clinical recovery, and the intraventricular administration of
amikacin was probably also an important contributing factor in
the patient’s clinical recovery. Unfortunately, 3 weeks after the
patient recovered and was discharged, he died of complications of
end-stage interstitial pneumonitis not related to Nocardia infection.
In conclusion, for the optimal antimicrobial treatment of
patients with nocardiosis, the treatment should be individualized
according to the species identiﬁcation, resistance proﬁle, and CNS
penetration capacity of the antimicrobial agent for use. In patients
with intracerebral Nocardia abscesses who deteriorate despite
optimal antimicrobial treatment, the use of immunotherapy with
IFN-g as adjuvant salvage therapy could be considered.
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